Stay updated on Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.

Latest updates to the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page
- CheckyesterdayChange DetectedNew and updated study locations were added (e.g., Taichung Veterans General Hospital in Taichung, Taiwan; Nanfang Hospital, Southern Medical University; Guangzhou, Guangdong, China 510515), and the total number of locations changed from 88 to 90. The page now includes additional navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates to the Intervention/Treatment header.SummaryDifference0.5%

- Check8 days agoChange DetectedA new revision entry labeled Revision: v3.5.5 with dates 2026-06-03 and 2026-06-02 was added to the page. The previous revision entry Revision: v3.5.4 with dates 2026-05-28 and 2026-05-27 appears to have been removed.SummaryDifference0.1%

- Check15 days agoChange DetectedAdded Nanjing Drum Tower Hospital in Nanjing, China and Johns Hopkins Myositis Center in Baltimore, MD as new study sites, increasing the total number of locations to 88.SummaryDifference0.5%

- Check22 days agoNo Change Detected
- Check29 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page, indicating a new version of the document. This appears to be an administrative update with no visible changes to the study details or data presented.SummaryDifference0.0%

- Check50 days agoChange DetectedThe record page reflects a newer update timestamp/version and expands the listed study sites by adding additional participating hospitals in Japan and China, increasing the total number of locations from 80 to 86. Other displayed changes are version/date-related rather than changes to trial design or key clinical details.SummaryDifference0.6%

- Check58 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

Stay in the know with updates to Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.